Vertex Pharmaceuticals Set to Release Q4 Earnings on February 12
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy VRTX?
Source: seekingalpha
- Earnings Announcement Schedule: Vertex Pharmaceuticals is set to announce its Q4 2023 earnings on February 12 after market close, with consensus EPS estimated at $5.15, reflecting a 29.4% year-over-year increase, and revenue expected to reach $3.17 billion, up 8.9% year-over-year.
- Historical Performance Review: Over the past two years, Vertex has exceeded EPS estimates 63% of the time and revenue estimates 75% of the time, indicating its strong profitability and market performance.
- Expectation Revision Dynamics: In the last three months, EPS estimates have seen five upward revisions and five downward adjustments, while revenue estimates have experienced seven upward revisions and six downward changes, reflecting analyst divergence and market uncertainty regarding the company's future performance.
- Industry Focus: During the upcoming earnings week, Vertex will be among the companies drawing attention alongside notable firms like Johnson & Johnson, Moderna, and Bristol Myers, potentially influencing investor sentiment towards the broader biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VRTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VRTX
Wall Street analysts forecast VRTX stock price to rise
22 Analyst Rating
17 Buy
5 Hold
0 Sell
Strong Buy
Current: 465.020
Low
414.00
Averages
515.88
High
604.00
Current: 465.020
Low
414.00
Averages
515.88
High
604.00
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vertex Pharmaceuticals Reports Strong Q4 2025 Earnings and 2026 Guidance
- Strong Financial Performance: Vertex Pharmaceuticals reported total revenue of $3.2 billion for Q4 2025, reflecting a 10% year-over-year increase, while full-year revenue reached $12 billion, up 9%, indicating sustained growth in the CF sector and successful product launches.
- New Product Progress: The next-generation CFTR modulator ALYFTREK demonstrated a significant mean reduction of 9.6 millimoles in sweat chloride in Phase III trials for 2- to 5-year-olds, with global regulatory submissions expected in the first half of 2026, further solidifying the company's leadership in the CF market.
- Market Expansion Plans: The company aims to triple JOURNAVX prescriptions in 2026 compared to approximately 550,000 in 2025, anticipating over $500 million in revenue contribution from non-CF products, showcasing strong confidence in market demand and growth potential.
- Investment and Expenditures: Non-GAAP operating expenses are projected to range between $5.65 billion and $5.75 billion in 2026, reflecting ongoing investments in late-stage clinical pipelines and commercial expansions to support new launches and revenue diversification.
See More
CRISPR Therapeutics: A Biotech Stock Poised for Growth
- Gene Editing Leader: CRISPR Therapeutics stands out as a leader in gene editing, utilizing CRISPR technology to repair specific genes for disease treatment, having secured the first-ever FDA approval for its CRISPR product, Casgevy, marking a significant breakthrough in the biotech industry.
- Massive Market Potential: The launch of Casgevy is gaining momentum, with CRISPR Therapeutics stating that the product has 'multi-billion-dollar potential'; although profits are shared with partner Vertex Pharmaceuticals, it still represents substantial growth opportunities for the company.
- Catalysts in 2026: The company expects to release clinical trial updates for cardiovascular candidate CTX310 and thromboembolic candidate CTX611 in the second half of 2026, along with trials for refractory hypertension and lung/liver disease, which could provide short-term stock support.
- Long-Term Growth Outlook: With a robust pipeline and the success of Casgevy, CRISPR Therapeutics is well-positioned for long-term growth, making it a stock that investors may regret missing out on in 2026.
See More
CRISPR Therapeutics Shows Growth Potential
- Technological Breakthrough: CRISPR Therapeutics received FDA approval for its first CRISPR product, Casgevy, marking a successful application of gene editing technology, which is expected to generate multi-billion-dollar revenue potential and further solidify its leadership in the biotech sector.
- Product Launch Progress: The market launch of Casgevy is gaining momentum, and although profits are shared with partner Vertex Pharmaceuticals, it still presents significant growth opportunities for CRISPR Therapeutics, reflecting the company's innovative capabilities in treating blood disorders.
- Future Catalysts: Multiple clinical trial updates are expected in the second half of 2026, including cardiovascular candidate CTX310 and thromboembolic candidate CTX611, which could provide short-term support for the stock price and enhance investor confidence.
- Pipeline Development: CRISPR Therapeutics plans to initiate clinical trials for refractory hypertension candidates in the first half of 2026 and for lung and liver disease candidates in mid-2026, establishing a robust product pipeline that lays a solid foundation for long-term growth.
See More
CRISPR Therapeutics Stock Rises Despite Poor Q4 Earnings
- Disappointing Earnings: CRISPR Therapeutics reported only $864,000 in revenue for Q4, resulting in a loss of $1.37 per share, significantly worse than analysts' expectations of a $1.20 loss, highlighting ongoing financial struggles.
- Partner Support: Despite CRISPR's poor revenue, its partner Vertex Pharmaceuticals anticipates over $500 million in revenue from non-cystic fibrosis products in 2026, indicating that CRISPR's gene-editing therapy Casgevy may achieve greater market potential in the future.
- Positive Market Reaction: CRISPR's stock rose 9.7% on Friday despite the disappointing earnings report, reflecting market optimism about its long-term growth potential, particularly in the innovative gene-editing sector.
- Future Outlook: Analysts project CRISPR's revenue to reach nearly $130 million in 2026, a significant increase from $3.5 million in 2025, although the company remains unprofitable, indicating market confidence in its product pipeline.
See More
Wall Street Rebounds as Inflation Data Surprises
- Inflation Data Decline: The annual inflation rate fell from 2.7% to 2.4% in January, undershooting the expected 2.5%, marking the lowest level since May 2025, indicating a potential economic slowdown that may prompt the Fed to consider interest rate cuts, thus impacting market liquidity.
- Core Inflation Eases: Core inflation, excluding food and energy, decreased from 2.7% to 2.5%, the lowest since March 2021, which could influence investor expectations regarding future interest rate policies and subsequently affect stock market performance.
- Small Caps Lead Gains: The Russell 2000 index rose nearly 1.8%, outperforming large-cap stocks, reflecting increased investor confidence in small businesses and potentially indicating optimism about economic recovery.
- Rivian Stock Surge: Rivian Automotive Inc. shares jumped 27%, marking the strongest day in the company's history, after reporting a narrower-than-expected quarterly loss, which may attract more investor interest in the electric vehicle market.
See More
Casgevy Therapy Revenue Shows Significant Growth
- Revenue Growth: Casgevy gene-editing therapy generated $54 million in Q4 2025 and $116 million for the full year, indicating strong market demand and significant business growth potential.
- Increased Patient Treatments: A total of 147 patients initiated treatment in 2025, nearly tripling from 2024, with 30 infusions occurring in Q4, reflecting heightened acceptance and confidence in the therapy.
- Pipeline Advancement: The company continues to advance its in vivo liver editing programs, with CTX310 in Phase 1b trials for lipid disorders and CTX321 progressing through enabling studies, with updates expected in the second half of 2026.
- Financial Position: CRISPR Therapeutics ended 2025 with $1.98 billion in cash and marketable securities, despite R&D expenses rising to $83.5 million in Q4 and net loss widening to $130.6 million, market confidence in its future growth remains strong.
See More
Vertex Pharmaceuticals Reports Strong Q4 2025 Earnings and 2026 Guidance
- Strong Financial Performance: Vertex Pharmaceuticals reported total revenue of $3.2 billion for Q4 2025, reflecting a 10% year-over-year increase, while full-year revenue reached $12 billion, up 9%, indicating sustained growth in the CF sector and successful product launches.
- New Product Progress: The next-generation CFTR modulator ALYFTREK demonstrated a significant mean reduction of 9.6 millimoles in sweat chloride in Phase III trials for 2- to 5-year-olds, with global regulatory submissions expected in the first half of 2026, further solidifying the company's leadership in the CF market.
- Market Expansion Plans: The company aims to triple JOURNAVX prescriptions in 2026 compared to approximately 550,000 in 2025, anticipating over $500 million in revenue contribution from non-CF products, showcasing strong confidence in market demand and growth potential.
- Investment and Expenditures: Non-GAAP operating expenses are projected to range between $5.65 billion and $5.75 billion in 2026, reflecting ongoing investments in late-stage clinical pipelines and commercial expansions to support new launches and revenue diversification.
See More
CRISPR Therapeutics: A Biotech Stock Poised for Growth
- Gene Editing Leader: CRISPR Therapeutics stands out as a leader in gene editing, utilizing CRISPR technology to repair specific genes for disease treatment, having secured the first-ever FDA approval for its CRISPR product, Casgevy, marking a significant breakthrough in the biotech industry.
- Massive Market Potential: The launch of Casgevy is gaining momentum, with CRISPR Therapeutics stating that the product has 'multi-billion-dollar potential'; although profits are shared with partner Vertex Pharmaceuticals, it still represents substantial growth opportunities for the company.
- Catalysts in 2026: The company expects to release clinical trial updates for cardiovascular candidate CTX310 and thromboembolic candidate CTX611 in the second half of 2026, along with trials for refractory hypertension and lung/liver disease, which could provide short-term stock support.
- Long-Term Growth Outlook: With a robust pipeline and the success of Casgevy, CRISPR Therapeutics is well-positioned for long-term growth, making it a stock that investors may regret missing out on in 2026.
See More
CRISPR Therapeutics Shows Growth Potential
- Technological Breakthrough: CRISPR Therapeutics received FDA approval for its first CRISPR product, Casgevy, marking a successful application of gene editing technology, which is expected to generate multi-billion-dollar revenue potential and further solidify its leadership in the biotech sector.
- Product Launch Progress: The market launch of Casgevy is gaining momentum, and although profits are shared with partner Vertex Pharmaceuticals, it still presents significant growth opportunities for CRISPR Therapeutics, reflecting the company's innovative capabilities in treating blood disorders.
- Future Catalysts: Multiple clinical trial updates are expected in the second half of 2026, including cardiovascular candidate CTX310 and thromboembolic candidate CTX611, which could provide short-term support for the stock price and enhance investor confidence.
- Pipeline Development: CRISPR Therapeutics plans to initiate clinical trials for refractory hypertension candidates in the first half of 2026 and for lung and liver disease candidates in mid-2026, establishing a robust product pipeline that lays a solid foundation for long-term growth.
See More
CRISPR Therapeutics Stock Rises Despite Poor Q4 Earnings
- Disappointing Earnings: CRISPR Therapeutics reported only $864,000 in revenue for Q4, resulting in a loss of $1.37 per share, significantly worse than analysts' expectations of a $1.20 loss, highlighting ongoing financial struggles.
- Partner Support: Despite CRISPR's poor revenue, its partner Vertex Pharmaceuticals anticipates over $500 million in revenue from non-cystic fibrosis products in 2026, indicating that CRISPR's gene-editing therapy Casgevy may achieve greater market potential in the future.
- Positive Market Reaction: CRISPR's stock rose 9.7% on Friday despite the disappointing earnings report, reflecting market optimism about its long-term growth potential, particularly in the innovative gene-editing sector.
- Future Outlook: Analysts project CRISPR's revenue to reach nearly $130 million in 2026, a significant increase from $3.5 million in 2025, although the company remains unprofitable, indicating market confidence in its product pipeline.
See More
Wall Street Rebounds as Inflation Data Surprises
- Inflation Data Decline: The annual inflation rate fell from 2.7% to 2.4% in January, undershooting the expected 2.5%, marking the lowest level since May 2025, indicating a potential economic slowdown that may prompt the Fed to consider interest rate cuts, thus impacting market liquidity.
- Core Inflation Eases: Core inflation, excluding food and energy, decreased from 2.7% to 2.5%, the lowest since March 2021, which could influence investor expectations regarding future interest rate policies and subsequently affect stock market performance.
- Small Caps Lead Gains: The Russell 2000 index rose nearly 1.8%, outperforming large-cap stocks, reflecting increased investor confidence in small businesses and potentially indicating optimism about economic recovery.
- Rivian Stock Surge: Rivian Automotive Inc. shares jumped 27%, marking the strongest day in the company's history, after reporting a narrower-than-expected quarterly loss, which may attract more investor interest in the electric vehicle market.
See More
Casgevy Therapy Revenue Shows Significant Growth
- Revenue Growth: Casgevy gene-editing therapy generated $54 million in Q4 2025 and $116 million for the full year, indicating strong market demand and significant business growth potential.
- Increased Patient Treatments: A total of 147 patients initiated treatment in 2025, nearly tripling from 2024, with 30 infusions occurring in Q4, reflecting heightened acceptance and confidence in the therapy.
- Pipeline Advancement: The company continues to advance its in vivo liver editing programs, with CTX310 in Phase 1b trials for lipid disorders and CTX321 progressing through enabling studies, with updates expected in the second half of 2026.
- Financial Position: CRISPR Therapeutics ended 2025 with $1.98 billion in cash and marketable securities, despite R&D expenses rising to $83.5 million in Q4 and net loss widening to $130.6 million, market confidence in its future growth remains strong.
See More
